Anti-migratory and increased cytotoxic effects of novel dual drug-loaded complex hybrid micelles in triple negative breast cancer cells

Nano Research

Volumn 8, Issue 8, 2015, Pages 2533-2547

  Kutty, Rajaletchumy Veloo ^a   Tay, Chor Yong ^a   Lim, Chen Siew ^a   Feng, Si Shen ^a,b   Leong, David Tai ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

biodegradable polymers; biomaterials; drug targeting; nanobiology; nanomedicine

Indexed keywords

EID: 84939269468     PISSN: 19980124     EISSN: 19980000     Source Type: Journal    
DOI: 10.1007/s12274-015-0760-8     Document Type: Article

References (65)

1. Baylin, S. B. Resistance, epigenetics and the cancer ecosystem. Nat. Med.2011, 17, 288–289.
2. Setyawati, M. I.; Tay, C. Y.; Leong, D. T. Exploiting cancer’s antioxidative weakness through p53 with nanotoxicology. Nanomedicine2014, 9, 369–371.
3. Jones, P. A.; Laird, P. W. Cancer epigenetics comes of age. Nat. Genet.1999, 21, 163–167.
4. Portela, A.; Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol.2010, 28, 1057–1068.
5. Wolffe, A. P.; Matzke, M. A. Epigenetics: Regulation through repression. Science1999, 286, 481–486.
6. Momparler, R. L. Cancer epigenetics. Oncogene2003, 22, 6479–6483.
7. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug Discov.2006, 5, 37–50.
8. Devinoy, E.; Rijnkels, M. Epigenetics in mammary gland biology and cancer. J. Mammary Gland Biol. Neoplasia2010, 15, 1–4.
9. Baylin, S. B.; Herman, J. G.; Graff, J. R.; Vertino, P. M.; Issa, J. P. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv. Cancer Res.1998, 72, 141–196.
10. Herman, J. G.; Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med.2003, 349, 2042–2054.
11. Grant, S.; Easley, C.; Kirkpatrick, P. V. Nat. Rev. Drug Discov.2007, 6, 21–22.
12. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol.2007, 25, 84–90.
13. Cortez, C. C.; Jones, P. A. Chromatin, cancer and drug therapies. Mutat. Res.-Fundam. Mol. Mech. Mutagen.2008, 647, 44–51.
14. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: Overview and perspectives. Mol. Cancer Res.2007, 5, 981–989.
15. Carew, J. S.; Giles, F. J.; Nawrocki, S. T. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett.2008, 269, 7–17.
16. McGrogan, B. T.; Gilmartin, B.; Carney, D. N.; McCann, A. Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta2008, 1785, 96–132.
17. Gascoigne, K. E.; Taylor, S. S. How do anti-mitotic drugs kill cancer cells? J. Cell Sci.2009, 122, 2579–2585.
18. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer2010, 10, 194–204.
19. Angelucci, A.; Mari, M.; Millimaggi, D.; Giusti, I.; Carta, G.; Bologna, M.; Dolo, V. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines. Gynecol. Oncol.2010, 119, 557–563.
20. Cooper, A. L.; Greenberg, V. L.; Lancaster, P. S.; van Nagell, J. R.; Zimmer, S. G.; Modesitt, S. C. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol. Oncol.2007, 104, 596–601.
21. Dietrich, C. S.; Greenberg, V. L.; DeSimone, C. P.; Modesitt, S. C.; van Nagell, J. R.; Craven, R.; Zimmer, S. G. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel induced apoptosis in ovarian cancer cell lines. Gynecol. Oncol.2010, 116, 126–130.
22. Cai, Y. Y.; Yap, C. W.; Wang, Z.; Ho, P. C.; Chan, S. Y.; Ng, K. Y.; Ge, Z. G.; Lin, H. S. Solubilization of vorinostat by cyclodextrins. J. Clin. Pharm. Ther.2010, 35, 521–526.
23. Hu, C. M. J.; Aryal, S.; Zhang, L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv.2010, 1, 323–334.
24. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res.2008, 14, 1310–1316.
25. Alexis, F.; Pridgen, E. M.; Langer, R.; Farokhzad, O. C. Nanoparticle technologies for cancer therapy. In Handbook of Experimental Pharmacology (Volume 197). Rosenthal, W., Ed. Springer Science+Business Media: Heidelberg, 2010, pp 55–86.
26. Xing, R.; Bhirde, A. A.; Wang, S.; Sun, X.; Liu, G.; Hou, Y.; Chen, X. Hollow iron oxide nanoparticles as multidrug resistant drug delivery and imaging vehicles. Nano Res.2012, 6, 1–9.
27. Chen, H.; Yeh, J.; Wang, L.; Khurshid, H.; Peng, N.; Wang, A. Y.; Mao, H. Preparation and control of the formation of single core and clustered nanoparticles for biomedical applications using a versatile amphiphilic diblock copolymer. Nano Res.2010, 3, 852–862.
28. Muthu, M. S.; Kutty, R. V.; Luo, Z.; Xie, J.; Feng, S. S. Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra bright gold nanoclusters. Biomaterials2014, 39, 234–248.
29. Li, Y.; Zheng, S.; Liang, X.; Jin, Y.; Wu, Y.; Bai, H.; Liu, R.; Dai, Z.; Liang Z.; Shi, T. Doping hydroxylated cationic lipid into PEGylated cerasome boosts in vivo siRNA transfection efficacy. Bioconjug. Chem.2014, 25, 2055–2066.
30. Tay, C. Y.; Yu, Y.; Setyawati, M. I.; Xie, J.; Leong, D. T. Presentation matters: Identity of gold nanocluster capping agent governs intracellular uptake and cell metabolism. Nano Res.2014, 7, 805–815.
31. Tay, C. Y.; Fang, W.; Setyawati, M. I.; Chia, S. L.; Tan, K. S.; Hsu, C.; Hong, C. H.; Leong, D. T. Nano-hydroxyapatite and nano-titanium dioxide exhibit different subcellular distribution and apoptotic profile in human oral epithelium. ACS Appl. Mater. Interfaces2014, 6, 6248–6256.
32. Setyawati, M. I.; Kutty, R. V.; Tay, C. Y.; Yuan, X.; Xie, J.; Leong, D. T. Novel theranostic DNA nanoscaffolds for the simultaneous detection and killing of Escherichia coli and Staphylococcus aureus. ACS Appl. Mater. Interfaces2014, 6, 21822–21831.
33. Setyawati, M. I.; Tay, C. Y.; Chia, S. L.; Goh, S. L.; Fang, W.; Neo, M. J.; Chong, H. C.; Tan, S. M.; Loo, S. C. J.; Ng, K. W. et al. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherin. Nat. Commun.2013, 4, 1673.
34. Tay, C. Y.; Setyawati, M. I.; Xie, J.; Parak, W. J.; Leong, D. T. Back to basics: Exploiting the innate physico-chemical characteristics of nanomaterials for biomedical applications. Adv. Funct. Mater.2014, 24, 5936–5955.
35. Leong, D. T.; Ng, K. W. Probing the relevance of 3D cancer models in nanomedicine research. Adv. Drug Deliv. Rev.2014, 79–80, 95–106.
36. Kutty, R. V.; Feng, S. S. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials2013, 34, 10160–10171.
37. Kutty, R. V.; Wei Leong, D. T.; Feng, S. S. Nanomedicine for the treatment of triple-negative breast cancer. Nanomedicine2014, 9, 561–564.
38. Sun, Z.; Wang, W.; Meng, J.; Chen, S.; Xu, H.; Yang, X. D. Multi-walled carbon nanotubes conjugated to tumor protein enhance the uptake of tumor antigens by human dendritic cells in vitro. Cell Res.2010, 20, 1170–1173.
39. Ma, K.; Wang, D. D.; Lin, Y.; Wang, J.; Petrenko, V.; Mao, C. Synergetic targeted delivery of sleeping-beauty transposon system to mesenchymal stem cells using LPD nanoparticles modified with a phage-displayed targeting peptide. Adv. Funct. Mater.2013, 23, 1172–1181.
40. Zhang, Z.; Tan, S.; Feng, S. S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials2012, 33, 4889–4906.
41. Mu, L.; Feng, S. S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J. Control. Release2002, 80, 129–144.
42. Muthu, M. S.; Leong, D. T.; Mei, L.; Feng, S. S. Nanotheranostics-Application and further development of nanomedicine strategies for advanced theranostics. Theranostics2014, 4, 660–677.
43. Sarfstein, R.; Bruchim, I.; Fishman, A.; Werner, H. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS One2011, 6, e24468.
44. Rodriguez, L. G.; Wu, X.; Guan, J. Wound-healing assay. Methods Mol. Biol.2005, 294, 23–29.
45. Sawant, R. R.; Torchilin, V. P. Polymeric micelles: Polyethylene glycol-Phosphatidylethanolamine (PEG-PE)-based micelles as an example. Methods Mol. Biol.2010, 624, 131–149.
46. Taurin, S.; Nehoff, H.; Greish, K. Anticancer nanomedicine and tumor vascular permeability: Where is the missing link? J. Control. Release2012, 164, 265–275.
47. Verma, M. S.; Liu, S. Y.; Chen, Y. Y.; Meerasa, A.; Gu, F. X. Size-tunable nanoparticles composed of dextran-b poly(D,Llactide) for drug delivery applications. Nano Res.2011, 5, 49–61.
48. Shan, X.; Yuan, Y.; Liu, C.; Tao, X.; Sheng, Y.; Xu, F. Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles. Biomed. Microdevices2009, 11, 1187–1194.
49. Gill, K. K.; Kaddoumi, A.; Nazzal, S. Mixed micelles of PEG2000-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: Enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur. J. Pharm. Sci.2012, 46, 64–71.
50. Mu, L.; Elbayoumi, T. A.; Torchilin, V. P. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and D-a-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int. J. Pharm.2005, 306, 142–149.
51. Owen, S. C.; Chan, D. P. Y.; Shoichet, M. S. Polymeric micelle stability. Nano Today2012, 7, 53–65.
52. Feng, S.S.; Zhao, L.; Zhang, Z.; Bhakta, G.; Win, K. Y.; Dong, Y.; Chien, S. Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo. Chem. Eng. Sci.2007, 62, 6641–6648.
53. Hasan, A. S.; Socha, M.; Lamprecht, A.; Ghazouani, F. E.; Sapin, A.; Hoffman, M.; Maincent, P.; Ubrich, N. Effect of the microencapsulation of nanoparticles on the reduction of burst release. Int. J. Pharm.2007, 344, 53–61.
54. Chiao, J.; Paradise, C.; Frankel, S. R.; Ramalingam, S. S.; Belani, C. Methods of treating cancers with SAHA, carboplatin, and paclitaxel and other combination therapies. U.S. Patent 20090105329, April 23, 2009.
55. Zhao, B.; Wang, X. Q.; Wang, X. Y.; Zhang, H.; Dai, W. B.; Wang, J.; Zhong, Z. L.; Wu, H. N.; Zhang, Q. Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure. Part. Fibre Toxicol.2013, 10, 47.
56. Tan, G. R.; Feng, S. S.; Leong, D. T. The reduction of anticancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. Biomaterials2014, 35, 3044–3051.
57. Modesitt, S. C.; Parsons, S. J. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter? Gynecol. Oncol.2010, 119, 351–357.
58. Mi, Y.; Liu, X. L.; Zhao, J.; Ding, J.; Feng, S. S. Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials2012, 33, 7519–7529.
59. Yvon, A. M. C.; Wadsworth, P.; Jordan, M. A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell1999, 10, 947–959.
60. Terzis, A. J.; Thorsen, F.; Heese, O.; Visted, T.; Bjerkvig, R.; Dahl, O.; Arnold, H.; Gundersen, G. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (taxol) in vitro. Br. J. Cancer1997, 75, 1744–1752.
61. An, Z.; Gluck, C. B.; Choy, M. L.; Kaufman, L. J. Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. Cancer Lett.2010, 292, 215–227.
62. Chong, W.; Li, Y.; Liu, B.; Zhao, T.; Fukudome, E. Y.; Liu, Z.; Smith, W. M.; Velmahos, G. C.; deMoya, M. A.; Alam, H. B. Histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates Toll-like receptor 4 signaling in lipopolysaccharide-stimulated mouse macrophages. J. Surg. Res.2012, 178, 851–859.
63. Westerlund, A.; Hujanen, E.; Höyhtyä, M.; Puistola, U.; Turpeenniemi-Hujanen, T. Ovarian cancer cell invasion is inhibited by paclitaxel. Clin. Exp. Metastasis1997, 15, 318–328.
64. Koo, C. X.; Fang, W.; Salto-Tellez, M.; Leong, D. T. Coexpressing shRNA with fluorescence tags for quantification of cell migration studies. Mol. Biol. Rep.2012, 39, 7695–7703.
65. Leong, D. T.; Lim, J.; Goh, X.; Pratap, J.; Pereira, B. P.; Kwok, H. S.; Nathan, S. S.; Dobson, J. R.; Lian, J. B.; Ito, Y. et al. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res.2010, 12, R89.